Medtronic plc (MDT) operating KPIs
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)
Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%
Medtronic diabetes Portfolio (Consolidated Segment) — U.S. Organic Revenue Growth YoY (%) (%)
Medtronic Form 8-K U.S. Revenue Tables
Latest, FY2026
1.2%
Period ended Apr 30, 2026
Change on a year earlier
-7.1 pts
8.3% in FY2025
History
5 years
Since FY2018
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diabetes Portfolio (Consolidated Segment) — U.S. Organic Revenue Growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2026 | Apr 30, 2026 | 1.2% | -7.1 pts | Medtronic SEC 8K_EARNINGS — FY2026Q4 (filed 2026-06-03) ↗ |
| FY2025 | Apr 30, 2025 | 8.3% | +7.9 pts | Medtronic SEC 8K_EARNINGS — FY2025Q4 (filed 2025-05-21) ↗ |
| FY2024 | Apr 30, 2024 | 0.4% | +13.2 pts | Medtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗ |
| FY2023 | Apr 30, 2023 | -12.8% | – | Medtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗ |
| FY2018 | Apr 30, 2018 | 7.0% | – | Medtronic SEC 8K_EARNINGS — FY2018Q4 (filed 2018-05-24) ↗ |
Cite this data
StockData. (2026). Medtronic Diabetes Portfolio (Consolidated Segment) — U.S. Organic Revenue Growth YoY (%) (%), annual FY2018–FY2026 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/diab-seg-us-org
See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.